A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

To evaluate the efficacy and safety of TQB6411 for injection in trial participant with advanced lung cancer

Trial Details

NCT ID
NCT07367529
Phase
PHASE1 / PHASE2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • TQB6411 for Injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

  • Participants voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance;
  • Age between 18 and 75 years (calculated based on the date of signing the informed consent form);
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
  • Expected survival greater than 12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →